The National Institute of Pharmaceutical Education and Research, Ahmedabad (NIPER-A), claims to have developed a new class of compounds for treatment of Type-II diabetes and also perfected the manufacturing process for it.
Its director Kiran Kalia, informed that the chemical molecules developed by her institute was different from other drugs available in the market. The institute,has filed application seeking patent for it.
“The drug was more efficient and cost effective than other drugs for diabetes available currently in the global market,” Kalia said.
The institute was, however, yet to approach the pharma companies for its commercial manufacturing and sale in the market.
The institute is also focussing on developing new drugs against tuberculosis and resistant TB strains, claimed that NIPER-A had developed as many as eight molecules exhibiting potent activity against Rifampicin-resistant strain of tuberculosis.
The institute conducts MS(Pharma) and doctoral courses. So far, a total of 284 students have passed out from the institute and 92 are currently studying for different postgraduate courses. A total of 15 students have enrolled for PhD programmes.
The institute, which is among seven national institutes set up in 2007 by the central government for postgraduate teaching and research in pharma, is currently operating from MB Institute of Mental Health in Ahmedabad.